Global leadership Team

Gisli Hennermark
CEO
Born: 1972
Education: MSc, Handelshögskolan i Stockholm.
Employed since: 2017
Previous Experience: Gisli was appointed CEO in 2015 with a background within the company as the Head of Latin America Sales. Gisli brings a broad entrepreneurial and business background from management consulting, such as Arthur D. Little, and his own successful ventures such as SamSari (trade sale, exit in 2010).
Other assignments: Board Member in Panasari AB, Espansari AB and Zipreneur AB.
Shareholding: 342 200 shares and 97 500 options.

Anna Ahlberg
CFO
Born: 1970
Employed since: 2018
Education: MBA, Gothenburg School of Economics and Commercial Law.
Previous Experience: Previously (amongst others) CFO and Head of Investor Relations in Q-Med AB, CFO and Head of Investor Relations in Vitrolife AB and Service Line Lead Spine and Orthopaedics and Head of Investor Relations in Global Health Partner AB. She brings an extensive knowledge about international growth companies and the legal requirements of listed companies.
Other assignments: Board member Irisity AB and Medistim ASA.
Shareholding: 22 500 shares and 32 500 options.

Ran Bronstein
President, Research & Development
Born: 1964
Education: M.Sc, The Hebrew University of Jerusalem.
Employed since: 1998
Previous Experience: Ran has been a pioneer in the field of Medical Simulation for over twenty years and oversees the whole group’s development operations. He started as one of the three founders of Simbionix, creating the vision of the company and leading the development of the medical simulators. Before joining the company, Ran co-founded Kidum Multimedia and managed its R&D team; a software company focused on 3-D technologies, which was acquired by SEA in 1997. Previously, Ran was a 3D and Simulation Project Leader at Tecnomatix Corporation.
Other assignments: –
Shareholding: 21 638 shares.

Anders Larsson
CTO
Born: 1973
Education: Mathematics & Computer Science, University of Gothenburg.
Employed since: 1999
Previous Experience: Anders is one of the co-founders of Surgical Science. He is a pioneer in the medical training simulation industry and a catalyst for continued innovation in medical simulation. He started in 1997 with his simulated laparoscopic suturing tasks and launched LapSim in 2000.
Other assignments: –
Shareholding: 47 500 shares and 37 500 options.

Inbal Mazor
VP Products & Marketing
Born: 1969
Education: B.Sc., Tel Aviv University and MBA in Marketing, Bar-Ilan University.
Employed since: 2000
Previous Experience: Inbal has been managing the marketing and product lines for over 20 years. She has a key role in building the medical simulation business and has been working with leading medical societies and key simulation partners throughout her career. Inbal began her career in marketing in the pharma industry at Novartis Pharma.
Other assignments: –
Shareholding: 18 543 shares.

Boaz Tal
COO
Born: 1968
Education: L.L.B. and BA in Accountancy and Economics, both from the Tel Aviv University.
Employed since: 2006
Previous experience: Boaz was appointed COO in 2021 after serving as the CFO of Simbionix since 2006. Boaz brings more than 25 years of finance, legal and operations experience. Before Simbionix, Boaz worked with Herzog, Fox & Neeman and PWC.
Other assignments: –
Shareholding: 18 543 shares.

Doron Zilberman
Vice President for International Sales
Born: 1962
Education: –
Employed since: 2000
Previous experience: Vice President for Sales, Applitec Ltd. (1995-2000), Vice President for International Sales and Business Development, Simbionix Ltd. (2000-2021).
Other assignments: –
Shareholding: 5 150 shares.

Niclas M Olsson
Executive Vice President, Industry/OEM
Born: 1966
Education: Computer Science, University of Lund.
Employed since: 2022
Previous Experience: Niclas was appointed Executive Vice President of Industry/OEM in May 2022. Niclas brings over 20 years of experience in healthcare-related sales, business development, operations, commercial partnerships, and strategy development from world-leading companies like Getinge Group and Synergy Health.
Other assignments: –
Shareholding: 27 000 options.